Insulin therapy is a century-long success story. Focus on basal insulin

• Alexander S. Ametov
• Yaroslava V. Pugovkina
• Polina S. Vovk

Abstract

Insulin was discovered 100 years ago, but interest in the study of this molecule does not Lose its relevance. The review reflects the evolution of basal insulin preparations from the moment of their creation to the present day. Much attention is paid to the fundamental differences in the mechanisms of protraction of basal insulin. The key features, advantages and disadvantages of individual drugs are highlighted, their comparative analysis is presented. It is important to note that the pharmacokinetics and pharmacodynamics of the "ideal" basal insulin should be as close as possible to the normal physiology of endogenous insulin. Improving the molecular properties of insulin through new analogs, combined with advances in glucose monitoring and dosing algorithms, will make insulin therapy safer and more effective for all diabetic patients.

Keywords:basal insulin basal insulin preparations, NPH insulin, insulin glargine, insulin detemir, insulin degludec, protraction, glycemic variability

References

1. Scheen A.J. Pathophysiology of insulin secretion. Ann Endocrinol (Paris). 2004; 65 (1): 29-36.

2. Hou J.C., Min L., Pessin J.E. Insulin granule biogenesis, trafficking and exocytosis. In: G. Litwack (ed.). Vitamins and Hormones Insulin and IGFs. 2009: 473-506.

3. Ametov A.S. The role of p-cells in regulation of glucose homeostasis in normal conditions and in type 2 diabetes mellitus. Sakharniy diabet [Diabetes Mellitus]. 2008; 11 (4): 6-11. (in Russian)

4. Rorsman P, Renstrom E. Insulin granule dynamics in pancreatic beta cells. Diabetologia. 2003; 46 (8): 1029-45.

5. Curry D.L., Bennett L.L., Grodsky G.M. Dynamics of insulin secretion by the perfused rat pancreas. Endocrinology. 1968; 83 (3): 572-84.

6. Donelan M.J., Morfini G., Julyan R., Sommers S., Hays L., Kajio H. Ca²⁺-dependent dephosphorylation of kinesin heavy chain on beta-granules in pancreatic beta-cells. Implications for regulated beta-granule transport and insulin exocytosis. J Biol Chem. 2002; 277 (27): 24 232-42.

7 Goeddel D.V., Kleid D.G., Bolivar F., Heyneker H.L., Yansura D.G., Crea R., et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci USA. 1979; 76: 106-10.

8. Miller W.L., Baxter J.D. Recombinant DNA - a new source of insulin. Diabetologia. 1980; 18: 431-6.

9. Cereghino G.P.L., Cregg J.M. Applications of yeast in biotechnology: protein production and genetic analysis. Curr Opin Biotechnol. 1999; 10: 422-7.

10. Soeborg T., Rasmussen C.H., Mosekilde E., Colding-Jorgensen M. Absorption kinetics of insulin after subcutaneous administration. Eur J Pharm Sci. 2009; 36: 78-90.

11. Yki-Jarvinen H., Dressler A., Ziemen M.; HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000; 23: 1130-6.

12. Ametov A.S., Pugovkina Ya.V. Glucose homeostasis and metabolic flexibility in healthy individuals. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (4): 12-22. DOI: https://doi.org/10.33029/2304-9529-2020-9-4-12-22 (in Russian)

13. Gusarov D.A., Gusarova V.D., Bairamashvili D.I., Mironov A.F. Human insulin and its pharmaceutical analogs. Biomeditsinskaya khimiya [Biomedical Chemistry]. 2008; 54 (6): 624-2. (in Russian)

14. Rosenstock J., Park G., Zimmerman J.; U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; 23: 1137-42.

15. Heise T., Pieber T.R. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007; 9: 648-59.

16. Ratner R.E., Hirsch I.B., Neifing J.L., Garg S.K., Mecca T.E., Wilson C.A. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000; 23: 639-43.

17. Home P.D., Fritsche A., Schinzel S., Massi-Benedetti M. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab. 2010; 12: 772-9.

18. Riddle M.C., Rosenstock J., Gerich J.; Insulin Glargine 4002 Study Investigators. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26: 3080-6.

19. Steinstraesser A., Schmidt R., Bergmann K., et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab. 2014; 16 (9): 873-6. DOI: https://doi.org/10.1111/dom.12283

20. Shestakova M.V., Galstyan G.R. Insulin glargine 300 U/ml in type 2 diabetes mellitus patients: results of the EDITION program (review). Prob-lemy endokrinologii [Problems of Endocrinology]. 2017; 63 (4): 257-68. DOI: https://doi.org/10.14341/probl2017634257-268 (in Russian)

21. Ritzel R., Roussel R., Bolli G.B., et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015; 17: 859-67

22. Dornhorst A., Ldddeke H.J., Sreenan S., et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007; 61: 523-8.

23. Danne T., Datz N., Endahl L., et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes. 2008; 9: 554-60.

24. Heise T., Hermanski L., Nosek L., Feldman A., Rasmussen S., Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012; 14: 859-64.

25. Heise T., Hovelmann U., Nosek L., et al. Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetologia. 2011; 54 (suppl 1): S 425.

26. Heise T., Meneghini L.F. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract. 2014; 20: 75-83.

27 Mathieu C., Hollander P, Miranda-Palma B., et al.; NN 1250-3770 (BEGIN: Flex T1) Trial Investigators. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013; 98: 1154-62.

28. Meneghini L., Atkin S.L., Gough S.C., et al.; NN 1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013; 36: 858-64.

29. Ratner R.E., Gough S.C.L., Mathieu C., et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013; 15: 175-84.

30. Lane W., Bailey T.S., Gerety G., et al. SWITCH 1: Reduced Hypoglycemia With Insulin Degludec (IDeg) vs Insulin Glargine (IGlar), both U 100, in Patients With T1D at High Risk of Hypoglycemia: A Randomized, Double-Blind, Crossover Trial [Abstract]. Presented at American Diabetes Association (ADA) 76^th Annual Scientific Sessions, 10-14 June 2016. New Orleans, LA, USA. Abstract number 87-LB.

31. Wysham C., Bhargava A., Chaykin L., et al. SWITCH 2: Reduced Hypoglycemia with Insulin Degludec (IDeg) vs. Insulin Glargine (IGlar), Both U 100, in Patients with T2D at High Risk of Hypoglycemia: A Randomized, DoubleBlind, Crossover Trial [Abstract]. Presented at American Diabetes Association (ADA) 76^th Annual Scientific Sessions, 10-14 June 2016. New Orleans, LA, USA. Abstract number 90-LB.

32. Hanefeld M., Fleischmann H., Landgraf W., Pistrosch F. EARLY-Studie: Frdhe Basalinsulintherapie unter realen Bedingungen bei Typ-2-Diabetikern. Diabetes Stoffwech H. 2012; 2: 91-7.

33. Ray K.K., Seshasai S.R., Wijesuriya S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009; 373 (9677): 1765-72.

34. Lee A.K., Warren B., Lee C.J., et al. The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care. 2018; 41 (1): 104-11.

35. Shestakova M.V. A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who start and intensify insulin treatment having never received it before. Sakharniy diabet [Diabetes Mellitus]. 2012; 15 (1): 63-70. DOI: https://doi.org/10.14341/2072-0351-5981 (in Russian)

36. Brod M., Rana A., Barnett A.H. Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians. Curr Med Res Opin. 2012; 28 (12): 1947-58. DOI: https://doi.org/10.1185/03007995.2012.743457

37. Rossetti P, Ampudia-Blasco F.J., Ascaso J.F. Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice. Diabetes Obes Metab. 2014; 16: 695-706.

38. Classification of diabetes mellitus. World Health Organization, 2019. URL: https://apps.who.int/iris/handle/10665/325182

39. Ahlqvist E., Storm P., Karajamaki A., et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018; 6 (5): 361-9.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)